Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity

Cited 4 time in webofscience Cited 0 time in scopus
  • Hit : 122
  • Download : 0
Recently, cyclodextrin (CD) has shown the potential for effective treatment of atherosclerotic plaques in mice by solubilizing plaque cholesterol. While promising as a new therapy for atherosclerosis, poor pharmacokinetics and ototoxicity of CD pose a therapeutic challenge. Thus far, however, there has been no attempts to overcome such limitations. Here, we showed that cyclodextrin polymer (CDP) with a diameter of similar to 10 nm exhibits outstanding pharmacokinetics and plaque targeting efficacy compared to a monomeric CD. Furthermore, we found out that CDP does not induce plasma membrane disruption as opposed to CD, which eliminated cytotoxicity and hemolytic activity of CD. In a mouse model of atherosclerosis, subcutaneous injections of beta-cyclodextrin polymer (beta CDP) significantly inhibited plaque growth compared to monomeric hydroxypropyl-beta-cyclodextrin (HP beta CD) at the same dose (1 g/kg). More importantly, beta CDP did not induce significant ototoxicity at a high-dose (8 g/kg) where HP beta CD reduced the outer hair cell content by 36%. These findings suggest that the polymerization of CD can overcome major limitations of CD therapy for treatment of atherosclerosis.
Publisher
ELSEVIER
Issue Date
2020-03
Language
English
Article Type
Article
Citation

JOURNAL OF CONTROLLED RELEASE, v.319, pp.77 - 86

ISSN
0168-3659
DOI
10.1016/j.jconrel.2019.12.021
URI
http://hdl.handle.net/10203/273694
Appears in Collection
BiS-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 4 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0